Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Gains from Sales and Divestitures (2020 - 2025)

Rein Therapeutics (RNTX) has disclosed Gains from Sales and Divestitures for 4 consecutive years, with $1.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Gains from Sales and Divestitures changed N/A to $1.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.0 million, a N/A change, with the full-year FY2022 number at $12500.0, changed N/A from a year prior.
  • Gains from Sales and Divestitures was $1.0 million for Q3 2025 at Rein Therapeutics, up from $12500.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $1.0 million in Q3 2025 to a low of $12500.0 in Q4 2022.
  • A 3-year average of $323214.3 and a median of $250000.0 in 2021 define the central range for Gains from Sales and Divestitures.
  • Peak YoY movement for Gains from Sales and Divestitures: soared 525.0% in 2021, then changed 0.0% in 2022.
  • Rein Therapeutics' Gains from Sales and Divestitures stood at $250000.0 in 2021, then tumbled by 95.0% to $12500.0 in 2022, then skyrocketed by 7900.0% to $1.0 million in 2025.
  • Per Business Quant, the three most recent readings for RNTX's Gains from Sales and Divestitures are $1.0 million (Q3 2025), $12500.0 (Q4 2022), and $250000.0 (Q3 2022).